- Home
- PGRE vs CGEM Comparison
PGRE vs CGEM Comparison
Compare PGRE & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- CGEM
- Stock Information
- Founded
- PGRE 1978
- CGEM 2016
- Country
- PGRE United States
- CGEM United States
- Employees
- PGRE N/A
- CGEM N/A
- Industry
- PGRE Real Estate Investment Trusts
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- CGEM Health Care
- Exchange
- PGRE Nasdaq
- CGEM Nasdaq
- Market Cap
- PGRE 1.0B
- CGEM 730.2M
- IPO Year
- PGRE 2014
- CGEM 2021
- Fundamental
- Price
- PGRE $4.97
- CGEM $12.39
- Analyst Decision
- PGRE Hold
- CGEM Strong Buy
- Analyst Count
- PGRE 3
- CGEM 7
- Target Price
- PGRE $4.50
- CGEM $31.67
- AVG Volume (30 Days)
- PGRE 1.0M
- CGEM 546.1K
- Earning Date
- PGRE 02-12-2025
- CGEM 11-07-2024
- Dividend Yield
- PGRE 1.42%
- CGEM N/A
- EPS Growth
- PGRE N/A
- CGEM N/A
- EPS
- PGRE N/A
- CGEM N/A
- Revenue
- PGRE $553,641,000.00
- CGEM N/A
- Revenue This Year
- PGRE N/A
- CGEM N/A
- Revenue Next Year
- PGRE N/A
- CGEM N/A
- P/E Ratio
- PGRE N/A
- CGEM N/A
- Revenue Growth
- PGRE N/A
- CGEM N/A
- 52 Week Low
- PGRE $4.21
- CGEM $10.00
- 52 Week High
- PGRE $5.47
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- PGRE 55.64
- CGEM 47.96
- Support Level
- PGRE $4.74
- CGEM $11.75
- Resistance Level
- PGRE $4.94
- CGEM $12.95
- Average True Range (ATR)
- PGRE 0.15
- CGEM 0.76
- MACD
- PGRE 0.02
- CGEM 0.19
- Stochastic Oscillator
- PGRE 88.24
- CGEM 77.69
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. Paramount Group derives nearly all of its revenue in the form of rental income from leasing its offices to tenants.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.